The Shanghai Food and Drug Safety Commission issued the “Fifteenth Five-Year Plan” for Ensuring Drug Safety and Promoting High-Quality Development of the Pharmaceutical Industry in Shanghai. Among them, it is proposed to strengthen targeted supervision of key areas and key varieties. Improve the implementation of contract production responsibilities and risk sharing mechanisms, and consolidate the main responsibility for quality and safety and the responsibilities agreed in quality agreements for outsourced production. Further promote the stationing of vaccine manufacturers in production for inspection. Implement full-coverage key supervision of vaccines, blood products, advanced therapeutic drugs, sterile drugs, special drugs, segmented production products, etc., to strengthen risk prevention and control in key areas such as data reliability, sterility assurance, deviation management, and change management. Strengthen supervision of key medical device varieties such as implants, sterile products, and selected from procurement, formulate a “one product, one policy” supervision plan for innovative medical devices, and strengthen inspections on procurement of key raw materials, inspection of finished products, and factory release. Implement actions to improve the production quality management system of cosmetics companies, strengthen supervision of key products such as special cosmetics and cosmetics using new ingredients, and strengthen raw material management.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.